 Uwe Christians
Concepts (1129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunosuppressive Agents | 133 | 2024 | 890 | 11.970 |
Why?
| | Sirolimus | 60 | 2025 | 276 | 6.940 |
Why?
| | Cyclosporine | 74 | 2019 | 268 | 6.490 |
Why?
| | Tandem Mass Spectrometry | 38 | 2025 | 532 | 5.420 |
Why?
| | Tacrolimus | 46 | 2019 | 199 | 4.360 |
Why?
| | Chromatography, High Pressure Liquid | 68 | 2024 | 597 | 4.330 |
Why?
| | Drug Monitoring | 23 | 2020 | 218 | 3.690 |
Why?
| | Kidney Transplantation | 46 | 2018 | 708 | 3.090 |
Why?
| | Chromatography, Liquid | 26 | 2024 | 433 | 2.570 |
Why?
| | Mycophenolic Acid | 15 | 2017 | 117 | 2.380 |
Why?
| | Metabolomics | 18 | 2022 | 678 | 2.290 |
Why?
| | Kidney | 25 | 2022 | 1468 | 2.230 |
Why?
| | Microsomes, Liver | 19 | 2019 | 86 | 2.100 |
Why?
| | Everolimus | 25 | 2020 | 91 | 2.050 |
Why?
| | Mass Spectrometry | 34 | 2021 | 739 | 1.830 |
Why?
| | Biomarkers | 28 | 2025 | 4149 | 1.690 |
Why?
| | Dronabinol | 15 | 2025 | 226 | 1.440 |
Why?
| | Graft Rejection | 26 | 2019 | 624 | 1.390 |
Why?
| | Liver Transplantation | 28 | 2018 | 871 | 1.320 |
Why?
| | Proteomics | 18 | 2024 | 1111 | 1.280 |
Why?
| | Cannabidiol | 7 | 2025 | 119 | 1.210 |
Why?
| | Plant Extracts | 6 | 2024 | 202 | 1.130 |
Why?
| | Cannabis | 12 | 2024 | 494 | 1.110 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 1.070 |
Why?
| | Oxidative Stress | 17 | 2019 | 1317 | 1.060 |
Why?
| | Cytochrome P-450 CYP3A | 20 | 2021 | 88 | 1.050 |
Why?
| | Rats | 62 | 2024 | 5647 | 1.030 |
Why?
| | Cannabinoids | 8 | 2024 | 161 | 1.020 |
Why?
| | Organ Transplantation | 10 | 2019 | 250 | 1.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2017 | 437 | 1.020 |
Why?
| | Hallucinogens | 6 | 2024 | 105 | 1.010 |
Why?
| | Humans | 239 | 2025 | 137585 | 1.000 |
Why?
| | Dried Blood Spot Testing | 3 | 2020 | 104 | 1.000 |
Why?
| | Pravastatin | 9 | 2021 | 41 | 0.990 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 8 | 2019 | 180 | 0.950 |
Why?
| | Hydrocortisone | 3 | 2025 | 322 | 0.940 |
Why?
| | Drug Interactions | 27 | 2025 | 410 | 0.940 |
Why?
| | Reproducibility of Results | 27 | 2025 | 3284 | 0.930 |
Why?
| | Cytochrome P-450 Enzyme System | 17 | 2019 | 155 | 0.910 |
Why?
| | Immunoassay | 3 | 2020 | 115 | 0.910 |
Why?
| | Metabolome | 5 | 2022 | 350 | 0.880 |
Why?
| | Animals | 120 | 2025 | 36940 | 0.840 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 262 | 0.820 |
Why?
| | Proteome | 5 | 2017 | 472 | 0.820 |
Why?
| | Mitochondria | 6 | 2017 | 948 | 0.820 |
Why?
| | Factor Xa Inhibitors | 2 | 2025 | 172 | 0.810 |
Why?
| | Drugs, Generic | 4 | 2019 | 22 | 0.800 |
Why?
| | Lovastatin | 7 | 2013 | 37 | 0.800 |
Why?
| | Intestinal Mucosa | 7 | 2017 | 623 | 0.760 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2015 | 445 | 0.760 |
Why?
| | Nucleotides | 2 | 2017 | 125 | 0.760 |
Why?
| | Male | 139 | 2025 | 67762 | 0.750 |
Why?
| | Isoprostanes | 4 | 2012 | 15 | 0.740 |
Why?
| | Biological Availability | 12 | 2019 | 148 | 0.740 |
Why?
| | Magnetic Resonance Spectroscopy | 18 | 2017 | 611 | 0.730 |
Why?
| | Pharmaceutical Preparations | 3 | 2017 | 179 | 0.730 |
Why?
| | Cortisone | 1 | 2021 | 12 | 0.730 |
Why?
| | United States Food and Drug Administration | 3 | 2020 | 208 | 0.730 |
Why?
| | Pregnanolone | 1 | 2021 | 37 | 0.700 |
Why?
| | TOR Serine-Threonine Kinases | 7 | 2016 | 412 | 0.700 |
Why?
| | Female | 115 | 2025 | 73304 | 0.700 |
Why?
| | Cyclosporins | 18 | 2001 | 76 | 0.690 |
Why?
| | Endocannabinoids | 5 | 2025 | 63 | 0.690 |
Why?
| | Urine | 2 | 2017 | 59 | 0.680 |
Why?
| | Transplant Recipients | 4 | 2019 | 184 | 0.680 |
Why?
| | Drug-Eluting Stents | 7 | 2025 | 81 | 0.670 |
Why?
| | Estrogen Receptor beta | 2 | 2012 | 40 | 0.670 |
Why?
| | Energy Metabolism | 17 | 2022 | 922 | 0.660 |
Why?
| | Dinoprost | 6 | 2019 | 44 | 0.650 |
Why?
| | Hemorrhage | 2 | 2025 | 722 | 0.650 |
Why?
| | Progesterone | 1 | 2021 | 254 | 0.640 |
Why?
| | Therapeutic Equivalency | 6 | 2019 | 32 | 0.630 |
Why?
| | Dose-Response Relationship, Drug | 25 | 2024 | 2057 | 0.630 |
Why?
| | Limit of Detection | 11 | 2024 | 85 | 0.620 |
Why?
| | Pharmacology | 1 | 2019 | 9 | 0.620 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 6 | 2004 | 48 | 0.610 |
Why?
| | Tissue Distribution | 12 | 2019 | 332 | 0.610 |
Why?
| | Signal Transduction | 11 | 2017 | 5079 | 0.590 |
Why?
| | Brain | 13 | 2019 | 2668 | 0.590 |
Why?
| | Models, Biological | 9 | 2021 | 1783 | 0.580 |
Why?
| | Therapies, Investigational | 1 | 2017 | 17 | 0.560 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.550 |
Why?
| | Intestine, Small | 5 | 2006 | 156 | 0.540 |
Why?
| | Toxicity Tests | 1 | 2017 | 37 | 0.540 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.540 |
Why?
| | Menopause | 3 | 2019 | 320 | 0.540 |
Why?
| | Rats, Wistar | 16 | 2024 | 455 | 0.530 |
Why?
| | Prenatal Exposure Delayed Effects | 6 | 2024 | 605 | 0.530 |
Why?
| | Cardiovascular Agents | 5 | 2025 | 159 | 0.530 |
Why?
| | Anticoagulants | 2 | 2020 | 664 | 0.510 |
Why?
| | Myocardium | 4 | 2017 | 1002 | 0.500 |
Why?
| | Anisakis | 1 | 2016 | 2 | 0.500 |
Why?
| | Helminth Proteins | 1 | 2016 | 24 | 0.500 |
Why?
| | Choline | 3 | 2022 | 127 | 0.490 |
Why?
| | Lipid Metabolism | 2 | 2017 | 518 | 0.480 |
Why?
| | Kidney Diseases | 3 | 2018 | 408 | 0.480 |
Why?
| | Fishes | 1 | 2016 | 105 | 0.470 |
Why?
| | Analgesics, Opioid | 8 | 2021 | 1000 | 0.470 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 320 | 0.460 |
Why?
| | Clinical Laboratory Techniques | 1 | 2015 | 97 | 0.460 |
Why?
| | Oxidoreductases, N-Demethylating | 6 | 2004 | 16 | 0.460 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 195 | 0.450 |
Why?
| | Sensitivity and Specificity | 12 | 2024 | 1946 | 0.440 |
Why?
| | Fingolimod Hydrochloride | 2 | 2024 | 40 | 0.440 |
Why?
| | Amino Acids | 3 | 2016 | 497 | 0.440 |
Why?
| | Premature Birth | 3 | 2025 | 333 | 0.430 |
Why?
| | Adult | 62 | 2025 | 37929 | 0.430 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 163 | 0.420 |
Why?
| | Polyenes | 8 | 1998 | 16 | 0.420 |
Why?
| | Hydroxyurea | 1 | 2013 | 35 | 0.420 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2013 | 37 | 0.420 |
Why?
| | Molecular Structure | 10 | 2014 | 489 | 0.420 |
Why?
| | Metabolic Clearance Rate | 9 | 2019 | 115 | 0.410 |
Why?
| | Protein Kinases | 4 | 2017 | 319 | 0.410 |
Why?
| | Anticholesteremic Agents | 4 | 2007 | 153 | 0.410 |
Why?
| | Piperazines | 4 | 2009 | 350 | 0.400 |
Why?
| | Coated Materials, Biocompatible | 3 | 2020 | 62 | 0.400 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 92 | 0.390 |
Why?
| | Pyrimidines | 4 | 2014 | 470 | 0.390 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 36 | 0.390 |
Why?
| | Middle Aged | 49 | 2025 | 33479 | 0.380 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2012 | 29 | 0.380 |
Why?
| | Drug Therapy, Combination | 18 | 2025 | 1066 | 0.380 |
Why?
| | Heart Transplantation | 8 | 2017 | 754 | 0.380 |
Why?
| | Administration, Oral | 12 | 2025 | 816 | 0.380 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2021 | 852 | 0.380 |
Why?
| | In Vitro Techniques | 18 | 2017 | 1092 | 0.380 |
Why?
| | Liver | 14 | 2023 | 1943 | 0.380 |
Why?
| | Vasomotor System | 1 | 2012 | 47 | 0.380 |
Why?
| | Hypoxia | 6 | 2024 | 1112 | 0.370 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2129 | 0.360 |
Why?
| | Macrophages, Alveolar | 4 | 2016 | 391 | 0.360 |
Why?
| | Lung Transplantation | 8 | 2000 | 313 | 0.350 |
Why?
| | Area Under Curve | 9 | 2021 | 314 | 0.350 |
Why?
| | Neonatal Abstinence Syndrome | 2 | 2021 | 24 | 0.350 |
Why?
| | Swine | 15 | 2017 | 775 | 0.350 |
Why?
| | Microsomes | 5 | 1998 | 33 | 0.340 |
Why?
| | Artifacts | 1 | 2011 | 129 | 0.340 |
Why?
| | Acetaminophen | 1 | 2013 | 268 | 0.330 |
Why?
| | Hydroxylation | 5 | 2019 | 39 | 0.330 |
Why?
| | Prospective Studies | 18 | 2025 | 7604 | 0.330 |
Why?
| | Young Adult | 24 | 2025 | 13209 | 0.320 |
Why?
| | Double-Blind Method | 11 | 2025 | 1993 | 0.320 |
Why?
| | Rats, Sprague-Dawley | 18 | 2023 | 2486 | 0.320 |
Why?
| | Calcineurin Inhibitors | 6 | 2014 | 72 | 0.320 |
Why?
| | Graft Survival | 6 | 2018 | 535 | 0.320 |
Why?
| | Phosphates | 5 | 2012 | 182 | 0.320 |
Why?
| | Drug Approval | 1 | 2010 | 88 | 0.310 |
Why?
| | Isoniazid | 2 | 2006 | 63 | 0.310 |
Why?
| | Lidocaine | 2 | 2023 | 42 | 0.310 |
Why?
| | Pain, Postoperative | 3 | 2018 | 265 | 0.310 |
Why?
| | Bile | 7 | 1992 | 34 | 0.310 |
Why?
| | Disease Models, Animal | 12 | 2024 | 4295 | 0.310 |
Why?
| | Cell Proliferation | 10 | 2020 | 2475 | 0.310 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 927 | 0.310 |
Why?
| | Theophylline | 2 | 2020 | 67 | 0.300 |
Why?
| | Time Factors | 19 | 2025 | 6828 | 0.300 |
Why?
| | Diltiazem | 3 | 1997 | 29 | 0.300 |
Why?
| | Glucose | 7 | 2017 | 1020 | 0.300 |
Why?
| | Marijuana Smoking | 3 | 2021 | 252 | 0.300 |
Why?
| | Flavanones | 1 | 2008 | 7 | 0.300 |
Why?
| | Drugs, Chinese Herbal | 1 | 2008 | 21 | 0.290 |
Why?
| | Paclitaxel | 3 | 2020 | 230 | 0.290 |
Why?
| | Pregnancy | 13 | 2025 | 6763 | 0.290 |
Why?
| | Medical Marijuana | 2 | 2021 | 117 | 0.290 |
Why?
| | Cross-Over Studies | 6 | 2025 | 564 | 0.290 |
Why?
| | HIV Protease Inhibitors | 3 | 2019 | 69 | 0.290 |
Why?
| | Child | 25 | 2022 | 21935 | 0.290 |
Why?
| | Neurons | 3 | 2019 | 1590 | 0.290 |
Why?
| | Liver Function Tests | 5 | 2025 | 114 | 0.280 |
Why?
| | Biotransformation | 18 | 2021 | 65 | 0.280 |
Why?
| | Calcium Channel Blockers | 3 | 1997 | 167 | 0.280 |
Why?
| | Buprenorphine | 2 | 2021 | 173 | 0.280 |
Why?
| | Adolescent | 29 | 2021 | 21513 | 0.280 |
Why?
| | Naltrexone | 1 | 2008 | 97 | 0.270 |
Why?
| | Angioplasty, Balloon | 3 | 2020 | 93 | 0.270 |
Why?
| | Drug Stability | 4 | 2013 | 167 | 0.260 |
Why?
| | Pyridostigmine Bromide | 1 | 2006 | 5 | 0.260 |
Why?
| | Lipase | 2 | 2020 | 69 | 0.260 |
Why?
| | Half-Life | 8 | 2019 | 164 | 0.260 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 30 | 0.260 |
Why?
| | Tachycardia | 1 | 2006 | 57 | 0.260 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2006 | 47 | 0.260 |
Why?
| | Coronary Artery Disease | 3 | 2025 | 698 | 0.250 |
Why?
| | Glomerular Filtration Rate | 8 | 2022 | 746 | 0.250 |
Why?
| | Anti-Bacterial Agents | 6 | 2025 | 1809 | 0.250 |
Why?
| | Reactive Oxygen Species | 4 | 2010 | 622 | 0.250 |
Why?
| | Macaca fascicularis | 13 | 2008 | 65 | 0.250 |
Why?
| | Fibrinolytic Agents | 2 | 2025 | 270 | 0.250 |
Why?
| | Drug Carriers | 2 | 2020 | 128 | 0.250 |
Why?
| | Regression Analysis | 5 | 2020 | 1024 | 0.250 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 46 | 0.250 |
Why?
| | Substance Abuse Detection | 3 | 2022 | 87 | 0.240 |
Why?
| | Dogs | 6 | 2025 | 413 | 0.240 |
Why?
| | Mice | 19 | 2025 | 17787 | 0.240 |
Why?
| | Drug Delivery Systems | 4 | 2020 | 365 | 0.240 |
Why?
| | Coronary Thrombosis | 1 | 2025 | 25 | 0.240 |
Why?
| | Pipecolic Acids | 1 | 2025 | 26 | 0.240 |
Why?
| | Mice, Knockout | 6 | 2019 | 3015 | 0.240 |
Why?
| | Epilepsy | 2 | 2020 | 333 | 0.240 |
Why?
| | Isomerism | 2 | 2024 | 56 | 0.240 |
Why?
| | Cell Line, Tumor | 8 | 2017 | 3412 | 0.240 |
Why?
| | Heptanoic Acids | 2 | 2007 | 66 | 0.240 |
Why?
| | Corticosterone | 2 | 2024 | 236 | 0.240 |
Why?
| | Wound Infection | 1 | 2025 | 32 | 0.230 |
Why?
| | Catheters | 2 | 2017 | 73 | 0.230 |
Why?
| | Caffeine | 1 | 2025 | 68 | 0.230 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 71 | 0.230 |
Why?
| | Drug Synergism | 7 | 2014 | 382 | 0.230 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.230 |
Why?
| | Cholic Acid | 1 | 2024 | 5 | 0.230 |
Why?
| | Oxylipins | 1 | 2025 | 40 | 0.230 |
Why?
| | Mitragyna | 1 | 2024 | 5 | 0.230 |
Why?
| | Inflammation | 9 | 2025 | 2837 | 0.230 |
Why?
| | Alkaloids | 1 | 2024 | 30 | 0.230 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2019 | 394 | 0.230 |
Why?
| | Infant, Newborn | 12 | 2024 | 6079 | 0.230 |
Why?
| | Ketorolac | 2 | 2017 | 20 | 0.230 |
Why?
| | Clemastine | 1 | 2024 | 1 | 0.230 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 840 | 0.220 |
Why?
| | Benzylidene Compounds | 2 | 2017 | 20 | 0.220 |
Why?
| | Diphosphonates | 1 | 2025 | 66 | 0.220 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.220 |
Why?
| | Acyl-CoA Dehydrogenases | 1 | 2024 | 12 | 0.220 |
Why?
| | Animals, Newborn | 3 | 2024 | 844 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 119 | 0.220 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2004 | 84 | 0.220 |
Why?
| | Pyrroles | 2 | 2007 | 213 | 0.220 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 28 | 0.220 |
Why?
| | Cholesterol | 5 | 2013 | 410 | 0.220 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1774 | 0.220 |
Why?
| | Mice, Inbred C57BL | 10 | 2024 | 5757 | 0.220 |
Why?
| | Kinetics | 8 | 2013 | 1670 | 0.210 |
Why?
| | Acidosis, Lactic | 1 | 2024 | 46 | 0.210 |
Why?
| | Anti-HIV Agents | 3 | 2013 | 778 | 0.210 |
Why?
| | Glycerides | 1 | 2024 | 21 | 0.210 |
Why?
| | Gestational Age | 3 | 2022 | 910 | 0.210 |
Why?
| | Protease Inhibitors | 1 | 2004 | 107 | 0.210 |
Why?
| | Cell Line | 7 | 2017 | 2847 | 0.210 |
Why?
| | Birth Weight | 2 | 2024 | 516 | 0.210 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 161 | 0.210 |
Why?
| | Morphine | 2 | 2018 | 158 | 0.210 |
Why?
| | Arachidonic Acids | 1 | 2024 | 62 | 0.210 |
Why?
| | Deoxycytidine | 1 | 2025 | 179 | 0.210 |
Why?
| | Niacinamide | 1 | 2024 | 82 | 0.210 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2006 | 242 | 0.210 |
Why?
| | Leukemia | 2 | 2020 | 240 | 0.210 |
Why?
| | Child, Preschool | 12 | 2024 | 11074 | 0.210 |
Why?
| | Macrolides | 1 | 2003 | 65 | 0.210 |
Why?
| | Rivaroxaban | 1 | 2025 | 255 | 0.200 |
Why?
| | Mixed Function Oxygenases | 5 | 2001 | 40 | 0.200 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 515 | 0.200 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.200 |
Why?
| | Transplantation | 4 | 2016 | 34 | 0.200 |
Why?
| | Adiponectin | 1 | 2025 | 244 | 0.200 |
Why?
| | Neurofibromatosis 1 | 2 | 2015 | 52 | 0.200 |
Why?
| | Blood Transfusion | 1 | 2025 | 325 | 0.200 |
Why?
| | Glycolysis | 4 | 2012 | 321 | 0.200 |
Why?
| | Psychomotor Performance | 1 | 2025 | 309 | 0.200 |
Why?
| | Blotting, Western | 8 | 2012 | 1226 | 0.190 |
Why?
| | Rats, Inbred Lew | 11 | 2012 | 114 | 0.190 |
Why?
| | White Matter | 1 | 2024 | 145 | 0.190 |
Why?
| | Glutamine | 3 | 2012 | 103 | 0.190 |
Why?
| | Hepatitis C | 1 | 2005 | 271 | 0.190 |
Why?
| | Infant, Small for Gestational Age | 1 | 2022 | 92 | 0.190 |
Why?
| | Fetal Growth Retardation | 2 | 2018 | 565 | 0.190 |
Why?
| | Pharmacogenetics | 3 | 2010 | 180 | 0.190 |
Why?
| | Kidney Failure, Chronic | 4 | 2017 | 570 | 0.190 |
Why?
| | Aminophylline | 2 | 2020 | 10 | 0.180 |
Why?
| | Heart Rate, Fetal | 1 | 2021 | 21 | 0.180 |
Why?
| | Homocysteine | 2 | 2019 | 156 | 0.180 |
Why?
| | Hepatectomy | 2 | 2023 | 251 | 0.180 |
Why?
| | Prostaglandins | 2 | 2019 | 97 | 0.180 |
Why?
| | Kynurenine | 2 | 2022 | 114 | 0.180 |
Why?
| | Biological Transport, Active | 5 | 2006 | 77 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 179 | 0.180 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 85 | 0.180 |
Why?
| | Transplantation, Heterologous | 3 | 2006 | 194 | 0.180 |
Why?
| | Pilot Projects | 8 | 2023 | 1710 | 0.180 |
Why?
| | Hypoxia-Ischemia, Brain | 2 | 2020 | 37 | 0.180 |
Why?
| | Arginine | 2 | 2025 | 271 | 0.180 |
Why?
| | Fetal Development | 2 | 2021 | 296 | 0.180 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2014 | 122 | 0.170 |
Why?
| | Pain | 2 | 2025 | 756 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2018 | 416 | 0.170 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 565 | 0.170 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 5 | 2012 | 114 | 0.170 |
Why?
| | Anesthetics, Intravenous | 2 | 2016 | 47 | 0.170 |
Why?
| | Hypothalamus | 2 | 2018 | 153 | 0.170 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2018 | 198 | 0.170 |
Why?
| | Heart Defects, Congenital | 2 | 2018 | 842 | 0.170 |
Why?
| | Organic Anion Transporters | 2 | 2011 | 12 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2023 | 233 | 0.170 |
Why?
| | Microspheres | 2 | 2020 | 137 | 0.170 |
Why?
| | Pyridines | 2 | 2017 | 506 | 0.170 |
Why?
| | Avoidance Learning | 2 | 2024 | 76 | 0.170 |
Why?
| | Complement Pathway, Alternative | 2 | 2018 | 122 | 0.170 |
Why?
| | Coronary Restenosis | 2 | 2010 | 21 | 0.170 |
Why?
| | Infant | 11 | 2024 | 9465 | 0.170 |
Why?
| | Keratosis | 1 | 2020 | 16 | 0.170 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 413 | 0.170 |
Why?
| | Treatment Outcome | 12 | 2025 | 10811 | 0.170 |
Why?
| | Glutamic Acid | 2 | 2018 | 246 | 0.170 |
Why?
| | Aged | 18 | 2025 | 23961 | 0.170 |
Why?
| | Lactones | 1 | 2000 | 56 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2024 | 350 | 0.170 |
Why?
| | Losartan | 1 | 2000 | 14 | 0.160 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2025 | 480 | 0.160 |
Why?
| | Tetrazoles | 1 | 2000 | 41 | 0.160 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 15 | 0.160 |
Why?
| | Amygdala | 3 | 2024 | 191 | 0.160 |
Why?
| | Complement Activation | 3 | 2018 | 415 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 56 | 0.160 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2017 | 122 | 0.160 |
Why?
| | Reference Standards | 5 | 2016 | 186 | 0.160 |
Why?
| | Milk, Human | 1 | 2021 | 158 | 0.160 |
Why?
| | Adenosine | 4 | 2017 | 225 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2000 | 117 | 0.160 |
Why?
| | Opiate Substitution Treatment | 1 | 2021 | 155 | 0.160 |
Why?
| | Mental Disorders | 2 | 2021 | 1077 | 0.160 |
Why?
| | Angiotensin II | 1 | 2000 | 99 | 0.160 |
Why?
| | Carotid Arteries | 2 | 2018 | 206 | 0.160 |
Why?
| | Hypothermia, Induced | 1 | 2020 | 80 | 0.160 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 114 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 86 | 0.160 |
Why?
| | Postoperative Complications | 5 | 2018 | 2654 | 0.160 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2253 | 0.160 |
Why?
| | Astrocytes | 4 | 2011 | 210 | 0.160 |
Why?
| | Case-Control Studies | 7 | 2025 | 3556 | 0.160 |
Why?
| | Age Factors | 7 | 2018 | 3295 | 0.160 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 17 | 0.160 |
Why?
| | Perfusion | 6 | 2017 | 213 | 0.160 |
Why?
| | Fentanyl | 2 | 2011 | 94 | 0.150 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 88 | 0.150 |
Why?
| | Leukotrienes | 1 | 2019 | 37 | 0.150 |
Why?
| | Spine | 1 | 2021 | 173 | 0.150 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2017 | 97 | 0.150 |
Why?
| | Vascular Diseases | 2 | 2019 | 243 | 0.150 |
Why?
| | Coronary Care Units | 1 | 2018 | 19 | 0.150 |
Why?
| | Bilirubin | 3 | 1995 | 97 | 0.150 |
Why?
| | Taurine | 1 | 2019 | 46 | 0.150 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 71 | 0.150 |
Why?
| | Imidazoles | 1 | 2000 | 238 | 0.150 |
Why?
| | Caspase 3 | 2 | 2017 | 246 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 101 | 0.150 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 180 | 0.150 |
Why?
| | Atmospheric Pressure | 3 | 2021 | 23 | 0.150 |
Why?
| | Legislation, Drug | 1 | 1999 | 80 | 0.150 |
Why?
| | Systems Biology | 1 | 2019 | 67 | 0.150 |
Why?
| | Complement Factor D | 1 | 2018 | 30 | 0.150 |
Why?
| | Wounds and Injuries | 1 | 2025 | 758 | 0.150 |
Why?
| | Homocystinuria | 1 | 2019 | 71 | 0.140 |
Why?
| | Naphthalenes | 1 | 1998 | 60 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 217 | 0.140 |
Why?
| | Phosphocreatine | 3 | 2004 | 46 | 0.140 |
Why?
| | DNA Damage | 2 | 2019 | 420 | 0.140 |
Why?
| | Creatinine | 5 | 2022 | 499 | 0.140 |
Why?
| | Iohexol | 1 | 2018 | 23 | 0.140 |
Why?
| | Excipients | 1 | 2018 | 55 | 0.140 |
Why?
| | Vascular Access Devices | 1 | 2018 | 26 | 0.140 |
Why?
| | Diet, Ketogenic | 1 | 2018 | 37 | 0.140 |
Why?
| | Reference Values | 4 | 2013 | 816 | 0.140 |
Why?
| | Lysophosphatidylcholines | 1 | 2017 | 22 | 0.140 |
Why?
| | Phospholipids | 5 | 2013 | 223 | 0.140 |
Why?
| | Phenylpropionates | 1 | 2017 | 19 | 0.140 |
Why?
| | Enzyme Activation | 2 | 2017 | 810 | 0.140 |
Why?
| | Genotype | 5 | 2019 | 1916 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 204 | 0.140 |
Why?
| | Glucuronides | 2 | 2022 | 18 | 0.140 |
Why?
| | Complement Factor B | 1 | 2018 | 109 | 0.140 |
Why?
| | Terbutaline | 1 | 2017 | 8 | 0.140 |
Why?
| | Sex Factors | 3 | 2019 | 2071 | 0.140 |
Why?
| | Cells, Cultured | 10 | 2017 | 4193 | 0.140 |
Why?
| | Endothelins | 1 | 2017 | 65 | 0.140 |
Why?
| | Pyridazines | 1 | 2017 | 56 | 0.140 |
Why?
| | Enzyme Stability | 1 | 2017 | 70 | 0.140 |
Why?
| | Acute Kidney Injury | 2 | 2018 | 815 | 0.140 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 119 | 0.130 |
Why?
| | Guanosine | 1 | 2017 | 41 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 4 | 2014 | 916 | 0.130 |
Why?
| | Endothelium | 2 | 2014 | 123 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2019 | 190 | 0.130 |
Why?
| | Complement Factor H | 1 | 2018 | 80 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2017 | 191 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2017 | 282 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 152 | 0.130 |
Why?
| | Quality Control | 4 | 2021 | 172 | 0.130 |
Why?
| | Glutathione | 4 | 2009 | 356 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 185 | 0.130 |
Why?
| | Cardiopulmonary Bypass | 1 | 2018 | 209 | 0.130 |
Why?
| | Plasma | 2 | 2017 | 212 | 0.130 |
Why?
| | Immunoglobulin M | 1 | 2018 | 289 | 0.130 |
Why?
| | Pregnancy Complications | 1 | 2021 | 527 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 69 | 0.130 |
Why?
| | Ischemia | 2 | 2012 | 409 | 0.130 |
Why?
| | Malathion | 1 | 2016 | 3 | 0.130 |
Why?
| | Necrosis | 1 | 2017 | 246 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1167 | 0.120 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2016 | 652 | 0.120 |
Why?
| | Vitamin D | 1 | 2019 | 397 | 0.120 |
Why?
| | Gastrectomy | 1 | 2017 | 126 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 316 | 0.120 |
Why?
| | Laboratory Proficiency Testing | 1 | 2015 | 10 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2007 | 135 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 1996 | 286 | 0.120 |
Why?
| | Tunica Intima | 2 | 2010 | 84 | 0.120 |
Why?
| | Mutation | 2 | 2022 | 3958 | 0.120 |
Why?
| | Propofol | 1 | 2016 | 73 | 0.120 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 257 | 0.120 |
Why?
| | Antipsychotic Agents | 1 | 2017 | 194 | 0.120 |
Why?
| | Imatinib Mesylate | 3 | 2009 | 79 | 0.120 |
Why?
| | Hepatocytes | 2 | 2006 | 220 | 0.120 |
Why?
| | Reperfusion Injury | 1 | 2018 | 279 | 0.120 |
Why?
| | Cerebral Cortex | 2 | 2024 | 433 | 0.120 |
Why?
| | Depression | 2 | 2021 | 1397 | 0.120 |
Why?
| | Sex Characteristics | 3 | 2023 | 762 | 0.120 |
Why?
| | Sulfonamides | 2 | 2025 | 513 | 0.120 |
Why?
| | Aerosols | 1 | 2016 | 176 | 0.120 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.120 |
Why?
| | HIV Infections | 3 | 2019 | 2836 | 0.110 |
Why?
| | Larva | 1 | 2016 | 226 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 99 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 350 | 0.110 |
Why?
| | Cholestasis | 3 | 1995 | 235 | 0.110 |
Why?
| | Extinction, Psychological | 1 | 2015 | 86 | 0.110 |
Why?
| | Benzamides | 3 | 2009 | 216 | 0.110 |
Why?
| | Piperidines | 1 | 2016 | 206 | 0.110 |
Why?
| | Substance-Related Disorders | 1 | 2023 | 1083 | 0.110 |
Why?
| | Pharmacokinetics | 3 | 2020 | 29 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2017 | 433 | 0.110 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.110 |
Why?
| | C-Reactive Protein | 3 | 2022 | 410 | 0.110 |
Why?
| | Tidal Volume | 1 | 2014 | 86 | 0.110 |
Why?
| | Specimen Handling | 1 | 2015 | 183 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 1692 | 0.110 |
Why?
| | Rabbits | 3 | 2017 | 794 | 0.110 |
Why?
| | United States | 5 | 2020 | 14841 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | DNA Methylation | 1 | 2019 | 643 | 0.110 |
Why?
| | Carbon Isotopes | 2 | 2024 | 144 | 0.110 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2006 | 195 | 0.110 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 79 | 0.110 |
Why?
| | Prognosis | 4 | 2018 | 4030 | 0.110 |
Why?
| | Mental Recall | 1 | 2015 | 202 | 0.110 |
Why?
| | Prostaglandin D2 | 1 | 2013 | 23 | 0.110 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2013 | 38 | 0.110 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 41 | 0.110 |
Why?
| | Altitude Sickness | 2 | 2006 | 153 | 0.110 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 43 | 0.110 |
Why?
| | Guidelines as Topic | 1 | 2015 | 275 | 0.100 |
Why?
| | Drug Resistance, Multiple | 3 | 2002 | 25 | 0.100 |
Why?
| | Apoptosis | 4 | 2017 | 2553 | 0.100 |
Why?
| | Fatty Acids | 2 | 2014 | 443 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2013 | 107 | 0.100 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.100 |
Why?
| | Brachial Artery | 3 | 2019 | 205 | 0.100 |
Why?
| | Adenosine Triphosphate | 4 | 2004 | 491 | 0.100 |
Why?
| | Schizophrenia | 1 | 2017 | 439 | 0.100 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 54 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1215 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.100 |
Why?
| | Cytoprotection | 1 | 2012 | 56 | 0.100 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.100 |
Why?
| | Aging | 2 | 2015 | 1864 | 0.100 |
Why?
| | Calibration | 4 | 2019 | 146 | 0.100 |
Why?
| | Iron | 2 | 2010 | 313 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 76 | 0.100 |
Why?
| | Graft vs Host Disease | 2 | 2000 | 252 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 2012 | 59 | 0.100 |
Why?
| | Gluconeogenesis | 1 | 2012 | 79 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 1 | 2018 | 530 | 0.100 |
Why?
| | Endothelial Cells | 2 | 2018 | 785 | 0.100 |
Why?
| | Integrins | 1 | 2012 | 95 | 0.090 |
Why?
| | Models, Theoretical | 3 | 2025 | 578 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 17 | 0.090 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2012 | 106 | 0.090 |
Why?
| | Fibronectins | 1 | 2012 | 133 | 0.090 |
Why?
| | Monitoring, Physiologic | 3 | 2012 | 275 | 0.090 |
Why?
| | Retrospective Studies | 9 | 2020 | 15657 | 0.090 |
Why?
| | Swine, Miniature | 2 | 2010 | 82 | 0.090 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2018 | 617 | 0.090 |
Why?
| | Lung Injury | 1 | 2014 | 219 | 0.090 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.090 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.090 |
Why?
| | Association Learning | 1 | 2012 | 61 | 0.090 |
Why?
| | Blood Volume | 1 | 2011 | 61 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 283 | 0.090 |
Why?
| | Vagus Nerve | 1 | 2012 | 86 | 0.090 |
Why?
| | Down Syndrome | 1 | 2018 | 496 | 0.090 |
Why?
| | Hot Flashes | 1 | 2012 | 87 | 0.090 |
Why?
| | Ritonavir | 1 | 2011 | 74 | 0.090 |
Why?
| | Morphine Derivatives | 1 | 2011 | 17 | 0.090 |
Why?
| | Lung | 9 | 2013 | 4060 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 167 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2015 | 556 | 0.090 |
Why?
| | Consumer Product Safety | 1 | 2011 | 33 | 0.090 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.090 |
Why?
| | Disease Progression | 4 | 2022 | 2757 | 0.090 |
Why?
| | Mutation, Missense | 1 | 2013 | 341 | 0.090 |
Why?
| | Cell Cycle | 2 | 2011 | 601 | 0.090 |
Why?
| | Internet | 1 | 2015 | 655 | 0.090 |
Why?
| | Survival Analysis | 2 | 2012 | 1325 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 849 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 263 | 0.090 |
Why?
| | Methylation | 1 | 2011 | 230 | 0.090 |
Why?
| | Tachyphylaxis | 1 | 2010 | 4 | 0.090 |
Why?
| | Cholinergic Agents | 1 | 2010 | 18 | 0.080 |
Why?
| | Structure-Activity Relationship | 5 | 2013 | 570 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2006 | 786 | 0.080 |
Why?
| | Verapamil | 2 | 2009 | 41 | 0.080 |
Why?
| | Trigonella | 1 | 2010 | 1 | 0.080 |
Why?
| | Graft Occlusion, Vascular | 2 | 2017 | 40 | 0.080 |
Why?
| | Needs Assessment | 1 | 2012 | 376 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 3196 | 0.080 |
Why?
| | Giant Cells | 1 | 2010 | 24 | 0.080 |
Why?
| | Sensation | 1 | 2010 | 53 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 294 | 0.080 |
Why?
| | Peptide Mapping | 1 | 2010 | 64 | 0.080 |
Why?
| | Tablets, Enteric-Coated | 2 | 2007 | 5 | 0.080 |
Why?
| | Twins, Dizygotic | 1 | 2010 | 175 | 0.080 |
Why?
| | Respiration, Artificial | 1 | 2014 | 645 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 474 | 0.080 |
Why?
| | Micromonosporaceae | 1 | 2009 | 2 | 0.080 |
Why?
| | Conditioning, Classical | 2 | 2024 | 103 | 0.080 |
Why?
| | Albuminuria | 1 | 2010 | 185 | 0.080 |
Why?
| | Neoplasms | 2 | 2016 | 2671 | 0.080 |
Why?
| | Proteinuria | 1 | 2010 | 97 | 0.080 |
Why?
| | Diclofenac | 1 | 2009 | 15 | 0.080 |
Why?
| | Antigens, Plant | 1 | 2010 | 54 | 0.080 |
Why?
| | Twins, Monozygotic | 1 | 2010 | 203 | 0.080 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2012 | 165 | 0.080 |
Why?
| | Risk Factors | 5 | 2025 | 10388 | 0.080 |
Why?
| | Cell Death | 1 | 2011 | 374 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 455 | 0.080 |
Why?
| | Infusions, Subcutaneous | 1 | 2009 | 23 | 0.080 |
Why?
| | Administration, Intravenous | 2 | 2021 | 155 | 0.080 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 5 | 2000 | 10 | 0.080 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 385 | 0.080 |
Why?
| | Loperamide | 1 | 2009 | 11 | 0.080 |
Why?
| | Radioimmunoassay | 6 | 1996 | 173 | 0.080 |
Why?
| | Cross Reactions | 2 | 2007 | 133 | 0.080 |
Why?
| | Surface Properties | 3 | 2019 | 413 | 0.080 |
Why?
| | Creatine | 2 | 2006 | 57 | 0.080 |
Why?
| | Oncogenes | 1 | 2009 | 116 | 0.080 |
Why?
| | Aorta | 2 | 2003 | 417 | 0.080 |
Why?
| | Rats, Inbred Strains | 3 | 2015 | 362 | 0.070 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2006 | 64 | 0.070 |
Why?
| | Species Specificity | 2 | 2008 | 585 | 0.070 |
Why?
| | Drug Evaluation | 2 | 2000 | 84 | 0.070 |
Why?
| | Lymphocyte Activation | 6 | 2003 | 1142 | 0.070 |
Why?
| | Kidney Medulla | 1 | 2008 | 35 | 0.070 |
Why?
| | Automation | 2 | 2016 | 95 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2025 | 956 | 0.070 |
Why?
| | Guinea Pigs | 1 | 2008 | 158 | 0.070 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 31 | 0.070 |
Why?
| | Hydroxybutyrates | 2 | 2005 | 14 | 0.070 |
Why?
| | Taste | 2 | 2024 | 229 | 0.070 |
Why?
| | Cytokines | 4 | 2025 | 2085 | 0.070 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 141 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 261 | 0.070 |
Why?
| | Gulf War | 2 | 2019 | 15 | 0.070 |
Why?
| | Oxidation-Reduction | 2 | 2009 | 1060 | 0.070 |
Why?
| | Rats, Inbred F344 | 1 | 2008 | 265 | 0.070 |
Why?
| | Delayed-Action Preparations | 3 | 2017 | 181 | 0.070 |
Why?
| | Macaca mulatta | 1 | 2008 | 166 | 0.070 |
Why?
| | Drug Combinations | 3 | 2024 | 343 | 0.070 |
Why?
| | Enzymes | 1 | 2008 | 67 | 0.070 |
Why?
| | Switzerland | 1 | 2007 | 37 | 0.070 |
Why?
| | Receptors, Nicotinic | 1 | 2010 | 334 | 0.070 |
Why?
| | Allergens | 1 | 2011 | 409 | 0.070 |
Why?
| | Antibiotics, Antineoplastic | 3 | 2011 | 127 | 0.070 |
Why?
| | Emulsions | 5 | 2016 | 53 | 0.070 |
Why?
| | Myocardial Infarction | 2 | 2007 | 1046 | 0.070 |
Why?
| | Acute Disease | 6 | 2005 | 1007 | 0.070 |
Why?
| | Nanoparticles | 1 | 2013 | 481 | 0.070 |
Why?
| | Autoanalysis | 1 | 2007 | 8 | 0.070 |
Why?
| | Prosthesis Design | 2 | 2025 | 327 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 278 | 0.070 |
Why?
| | NAD | 2 | 2004 | 77 | 0.070 |
Why?
| | Serum Albumin | 3 | 2019 | 150 | 0.070 |
Why?
| | ATP-Binding Cassette Transporters | 2 | 2013 | 137 | 0.070 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2019 | 2189 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2007 | 75 | 0.070 |
Why?
| | Narcotic Antagonists | 1 | 2008 | 181 | 0.060 |
Why?
| | Caco-2 Cells | 3 | 2003 | 77 | 0.060 |
Why?
| | Cardiotonic Agents | 1 | 2007 | 124 | 0.060 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5131 | 0.060 |
Why?
| | Immune Tolerance | 3 | 2017 | 363 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 45 | 0.060 |
Why?
| | Fetus | 2 | 2021 | 806 | 0.060 |
Why?
| | Epithelial Cells | 1 | 2012 | 1096 | 0.060 |
Why?
| | Lactic Acid | 4 | 2009 | 305 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 558 | 0.060 |
Why?
| | Macaca | 1 | 2006 | 56 | 0.060 |
Why?
| | Food-Drug Interactions | 1 | 2005 | 9 | 0.060 |
Why?
| | Liver Diseases | 2 | 2024 | 315 | 0.060 |
Why?
| | Nitric Oxide | 3 | 2017 | 915 | 0.060 |
Why?
| | Hematopoietic Stem Cells | 1 | 2009 | 406 | 0.060 |
Why?
| | Body Weight | 5 | 2001 | 985 | 0.060 |
Why?
| | Growth Inhibitors | 1 | 2005 | 43 | 0.060 |
Why?
| | Technology, Pharmaceutical | 1 | 2005 | 30 | 0.060 |
Why?
| | Exercise | 1 | 2017 | 2057 | 0.060 |
Why?
| | Lactates | 1 | 2005 | 85 | 0.060 |
Why?
| | Syndrome | 1 | 2006 | 358 | 0.060 |
Why?
| | Methylamines | 1 | 2005 | 34 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 102 | 0.060 |
Why?
| | Ships | 1 | 1985 | 5 | 0.060 |
Why?
| | Posture | 1 | 2006 | 185 | 0.060 |
Why?
| | Ultrasonics | 2 | 2002 | 49 | 0.060 |
Why?
| | Phosphorylation | 5 | 2012 | 1759 | 0.060 |
Why?
| | Organ Size | 3 | 2015 | 477 | 0.060 |
Why?
| | Iliac Artery | 2 | 2017 | 55 | 0.060 |
Why?
| | Deuterium | 1 | 2005 | 99 | 0.060 |
Why?
| | Streptozocin | 1 | 2005 | 21 | 0.060 |
Why?
| | CD55 Antigens | 1 | 2005 | 30 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 642 | 0.060 |
Why?
| | Hot Temperature | 2 | 2012 | 391 | 0.060 |
Why?
| | Triglycerides | 3 | 2011 | 524 | 0.060 |
Why?
| | Insulin Infusion Systems | 1 | 2009 | 394 | 0.060 |
Why?
| | Paraplegia | 1 | 1985 | 60 | 0.060 |
Why?
| | Complement Inactivator Proteins | 1 | 2005 | 42 | 0.060 |
Why?
| | Hippocampus | 1 | 2010 | 895 | 0.060 |
Why?
| | Colorado | 5 | 2021 | 4565 | 0.060 |
Why?
| | Warfarin | 1 | 2006 | 154 | 0.060 |
Why?
| | Drug Design | 1 | 2005 | 167 | 0.060 |
Why?
| | Troleandomycin | 3 | 1999 | 16 | 0.060 |
Why?
| | Steroids | 2 | 2005 | 167 | 0.060 |
Why?
| | Saccharin | 1 | 2024 | 6 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2005 | 71 | 0.060 |
Why?
| | Consensus | 2 | 2019 | 683 | 0.060 |
Why?
| | Pulmonary Artery | 2 | 2007 | 1086 | 0.060 |
Why?
| | Vasodilation | 2 | 2018 | 499 | 0.060 |
Why?
| | Receptors, Complement | 1 | 2005 | 122 | 0.060 |
Why?
| | Stress, Psychological | 2 | 2025 | 1100 | 0.060 |
Why?
| | Calcineurin | 2 | 2004 | 108 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 28 | 0.050 |
Why?
| | Cholesterol, HDL | 2 | 2013 | 203 | 0.050 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 801 | 0.050 |
Why?
| | Trimethylsilyl Compounds | 1 | 2004 | 5 | 0.050 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.050 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 25 | 0.050 |
Why?
| | Diabetes Mellitus | 1 | 2013 | 1040 | 0.050 |
Why?
| | Isotopes | 1 | 2024 | 33 | 0.050 |
Why?
| | Antitubercular Agents | 1 | 2005 | 206 | 0.050 |
Why?
| | Tomography, Optical Coherence | 1 | 2025 | 213 | 0.050 |
Why?
| | Glycerol | 1 | 2024 | 94 | 0.050 |
Why?
| | Analysis of Variance | 2 | 1997 | 1316 | 0.050 |
Why?
| | Obesity | 1 | 2017 | 2992 | 0.050 |
Why?
| | DNA | 2 | 2009 | 1459 | 0.050 |
Why?
| | Midazolam | 1 | 2003 | 56 | 0.050 |
Why?
| | Oxidative Phosphorylation | 1 | 2004 | 193 | 0.050 |
Why?
| | Plant Leaves | 1 | 2024 | 147 | 0.050 |
Why?
| | Protein Binding | 3 | 2018 | 2224 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2025 | 317 | 0.050 |
Why?
| | Insulin | 3 | 2009 | 2409 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2005 | 202 | 0.050 |
Why?
| | Tumor Cells, Cultured | 3 | 2001 | 955 | 0.050 |
Why?
| | NADP | 2 | 1994 | 49 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2009 | 879 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 2 | 2018 | 39 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 2295 | 0.050 |
Why?
| | Pancreas Transplantation | 1 | 2003 | 75 | 0.050 |
Why?
| | Altitude | 3 | 2017 | 488 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2015 | 5778 | 0.050 |
Why?
| | Trauma Centers | 1 | 2025 | 421 | 0.050 |
Why?
| | Renal Insufficiency | 1 | 2005 | 162 | 0.050 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2000 | 105 | 0.050 |
Why?
| | Leukocytes | 1 | 2024 | 311 | 0.050 |
Why?
| | Ketoconazole | 2 | 1999 | 4 | 0.050 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 3 | 2010 | 340 | 0.050 |
Why?
| | Cognition | 2 | 2023 | 1153 | 0.050 |
Why?
| | Isoflurane | 1 | 2002 | 31 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2024 | 167 | 0.050 |
Why?
| | Oligodendroglia | 1 | 2024 | 179 | 0.050 |
Why?
| | Sports | 1 | 1985 | 231 | 0.050 |
Why?
| | Oral Mucosal Absorption | 1 | 2021 | 1 | 0.050 |
Why?
| | Hepatobiliary Elimination | 1 | 2021 | 1 | 0.050 |
Why?
| | Reperfusion | 1 | 2002 | 40 | 0.050 |
Why?
| | Administration, Sublingual | 1 | 2021 | 12 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 545 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2021 | 5472 | 0.050 |
Why?
| | Wine | 1 | 2001 | 12 | 0.050 |
Why?
| | Drug Dosage Calculations | 1 | 2021 | 23 | 0.050 |
Why?
| | Plant Preparations | 1 | 2002 | 36 | 0.050 |
Why?
| | Oxaloacetic Acid | 1 | 2001 | 4 | 0.050 |
Why?
| | Drug Overdose | 1 | 2006 | 347 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2001 | 58 | 0.050 |
Why?
| | Biological Transport | 2 | 2003 | 418 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 298 | 0.040 |
Why?
| | Psychotropic Drugs | 1 | 2002 | 68 | 0.040 |
Why?
| | Cell Survival | 3 | 2012 | 1120 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2002 | 116 | 0.040 |
Why?
| | Aspartic Acid | 1 | 2001 | 79 | 0.040 |
Why?
| | Behavior, Animal | 1 | 2024 | 501 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 114 | 0.040 |
Why?
| | Glomerular Mesangium | 2 | 1991 | 21 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2021 | 78 | 0.040 |
Why?
| | Microchemistry | 3 | 2000 | 20 | 0.040 |
Why?
| | Tryptophan | 1 | 2022 | 183 | 0.040 |
Why?
| | Haplotypes | 2 | 2013 | 494 | 0.040 |
Why?
| | Gene Silencing | 2 | 2012 | 195 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 440 | 0.040 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2000 | 49 | 0.040 |
Why?
| | Membrane Glycoproteins | 2 | 2001 | 500 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2013 | 343 | 0.040 |
Why?
| | Predictive Value of Tests | 2 | 2018 | 2031 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 237 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2020 | 1738 | 0.040 |
Why?
| | Aorta, Abdominal | 1 | 2000 | 46 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2000 | 9 | 0.040 |
Why?
| | Pyrazoles | 1 | 2004 | 423 | 0.040 |
Why?
| | LLC-PK1 Cells | 1 | 2000 | 18 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2000 | 272 | 0.040 |
Why?
| | Antimetabolites | 1 | 2000 | 23 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 148 | 0.040 |
Why?
| | Reward | 1 | 2022 | 244 | 0.040 |
Why?
| | Logistic Models | 2 | 2022 | 2074 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 475 | 0.040 |
Why?
| | Risk Assessment | 3 | 2018 | 3457 | 0.040 |
Why?
| | Pulmonary Alveoli | 1 | 2002 | 405 | 0.040 |
Why?
| | Heart | 1 | 2003 | 655 | 0.040 |
Why?
| | Transplantation, Heterotopic | 1 | 1999 | 18 | 0.040 |
Why?
| | Blood Glucose | 2 | 2009 | 2186 | 0.040 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2019 | 81 | 0.040 |
Why?
| | Rats, Inbred BN | 4 | 2000 | 58 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2020 | 184 | 0.040 |
Why?
| | Attention | 1 | 2023 | 427 | 0.040 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.040 |
Why?
| | Citrus | 1 | 1999 | 8 | 0.040 |
Why?
| | K562 Cells | 2 | 2009 | 89 | 0.040 |
Why?
| | Pituitary-Adrenal System | 1 | 2020 | 162 | 0.040 |
Why?
| | Antibodies, Monoclonal | 3 | 2001 | 1430 | 0.040 |
Why?
| | Epithelium | 1 | 2000 | 313 | 0.040 |
Why?
| | Diet | 2 | 2019 | 1278 | 0.040 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2020 | 197 | 0.040 |
Why?
| | Beverages | 1 | 1999 | 69 | 0.040 |
Why?
| | Maternal Age | 1 | 2019 | 129 | 0.040 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.040 |
Why?
| | Individuality | 1 | 2000 | 156 | 0.040 |
Why?
| | Antigens, CD | 1 | 2001 | 521 | 0.040 |
Why?
| | Amides | 1 | 1999 | 93 | 0.040 |
Why?
| | Complement C5a | 1 | 2018 | 71 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 206 | 0.040 |
Why?
| | Ultrafiltration | 1 | 2018 | 28 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 160 | 0.040 |
Why?
| | Drug Liberation | 1 | 2018 | 35 | 0.040 |
Why?
| | Europe | 1 | 1999 | 414 | 0.040 |
Why?
| | Sus scrofa | 1 | 2018 | 52 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2014 | 1178 | 0.040 |
Why?
| | F2-Isoprostanes | 2 | 2009 | 21 | 0.040 |
Why?
| | Nitriles | 1 | 1999 | 172 | 0.040 |
Why?
| | Hypertension | 1 | 2007 | 1295 | 0.040 |
Why?
| | Ions | 1 | 2018 | 70 | 0.040 |
Why?
| | Solutions | 2 | 2016 | 168 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 78 | 0.040 |
Why?
| | Serum Albumin, Bovine | 1 | 2018 | 64 | 0.040 |
Why?
| | Bioreactors | 1 | 2018 | 42 | 0.040 |
Why?
| | Nifedipine | 1 | 1997 | 29 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 405 | 0.040 |
Why?
| | Hyperlipidemias | 1 | 1998 | 120 | 0.030 |
Why?
| | Urea | 1 | 2018 | 81 | 0.030 |
Why?
| | Bronchi | 1 | 1999 | 260 | 0.030 |
Why?
| | Weight Gain | 1 | 2001 | 519 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1998 | 106 | 0.030 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 434 | 0.030 |
Why?
| | Food Hypersensitivity | 2 | 2011 | 183 | 0.030 |
Why?
| | Intestines | 1 | 2000 | 357 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 2011 | 206 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 186 | 0.030 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2017 | 69 | 0.030 |
Why?
| | Postoperative Care | 1 | 1999 | 261 | 0.030 |
Why?
| | Archaeal Proteins | 1 | 2017 | 50 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 1035 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2013 | 2139 | 0.030 |
Why?
| | Cholesterol, VLDL | 1 | 1996 | 5 | 0.030 |
Why?
| | Stroke | 1 | 2006 | 1120 | 0.030 |
Why?
| | Schizophrenic Psychology | 1 | 2017 | 94 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2008 | 156 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 370 | 0.030 |
Why?
| | Postmenopause | 1 | 2019 | 366 | 0.030 |
Why?
| | Hydrolysis | 2 | 2013 | 177 | 0.030 |
Why?
| | Temperature | 1 | 2000 | 679 | 0.030 |
Why?
| | Pharmacogenomic Testing | 1 | 2017 | 64 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2013 | 2900 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2019 | 188 | 0.030 |
Why?
| | Cytochrome P-450 CYP2E1 | 1 | 1996 | 31 | 0.030 |
Why?
| | Catheterization | 1 | 2017 | 179 | 0.030 |
Why?
| | Cell Count | 2 | 2013 | 324 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 73 | 0.030 |
Why?
| | Anterior Chamber | 1 | 1996 | 22 | 0.030 |
Why?
| | Anesthesia, Intravenous | 1 | 2016 | 16 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 674 | 0.030 |
Why?
| | Materials Testing | 1 | 2018 | 356 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2016 | 42 | 0.030 |
Why?
| | Nutritional Status | 1 | 2019 | 350 | 0.030 |
Why?
| | Bromocriptine | 1 | 1996 | 30 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2010 | 2531 | 0.030 |
Why?
| | Nonlinear Dynamics | 1 | 2016 | 88 | 0.030 |
Why?
| | Gastric Mucosa | 1 | 1996 | 55 | 0.030 |
Why?
| | Duodenum | 1 | 1996 | 78 | 0.030 |
Why?
| | Women's Health | 1 | 2019 | 372 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2389 | 0.030 |
Why?
| | Nicotinic Agonists | 1 | 2017 | 129 | 0.030 |
Why?
| | Infant, Premature | 1 | 2020 | 574 | 0.030 |
Why?
| | Syringes | 1 | 2016 | 44 | 0.030 |
Why?
| | Artificial Organs | 1 | 1995 | 2 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Epitopes | 1 | 2018 | 479 | 0.030 |
Why?
| | Health Policy | 1 | 1999 | 388 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 656 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2007 | 1910 | 0.030 |
Why?
| | Incidence | 2 | 2018 | 2804 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 672 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 43 | 0.030 |
Why?
| | Neuroglia | 1 | 1996 | 173 | 0.030 |
Why?
| | Estradiol | 1 | 2019 | 521 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2016 | 409 | 0.030 |
Why?
| | Citric Acid Cycle | 2 | 2010 | 57 | 0.030 |
Why?
| | Asialoglycoproteins | 1 | 1995 | 2 | 0.030 |
Why?
| | Safety | 1 | 2017 | 338 | 0.030 |
Why?
| | Complement System Proteins | 1 | 2018 | 327 | 0.030 |
Why?
| | Precision Medicine | 1 | 2019 | 429 | 0.030 |
Why?
| | Rhodamines | 1 | 1995 | 20 | 0.030 |
Why?
| | Extracellular Matrix | 2 | 1996 | 528 | 0.030 |
Why?
| | alpha-Fetoproteins | 1 | 1995 | 46 | 0.030 |
Why?
| | Heat-Shock Proteins | 2 | 2007 | 143 | 0.030 |
Why?
| | Uteroglobin | 1 | 2014 | 23 | 0.030 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 18 | 0.030 |
Why?
| | Oxides | 1 | 1995 | 46 | 0.030 |
Why?
| | Pain Measurement | 2 | 2010 | 521 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 411 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2017 | 257 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2019 | 390 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 1996 | 365 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 394 | 0.030 |
Why?
| | Ferric Compounds | 1 | 1995 | 56 | 0.030 |
Why?
| | Nitrites | 1 | 2014 | 84 | 0.030 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.030 |
Why?
| | Kidney Function Tests | 3 | 2006 | 160 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 688 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 54 | 0.030 |
Why?
| | Nitrates | 1 | 2014 | 92 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2018 | 911 | 0.030 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 18 | 0.030 |
Why?
| | Interleukin-2 | 1 | 2015 | 455 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 123 | 0.030 |
Why?
| | Insufflation | 1 | 2013 | 12 | 0.030 |
Why?
| | Nevirapine | 1 | 2013 | 17 | 0.030 |
Why?
| | Benzoxazines | 1 | 2013 | 31 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2013 | 90 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 2 | 1999 | 86 | 0.030 |
Why?
| | Alkynes | 1 | 2013 | 56 | 0.030 |
Why?
| | Phospholipases | 1 | 2013 | 14 | 0.030 |
Why?
| | Cognition Disorders | 1 | 2017 | 496 | 0.030 |
Why?
| | Mannitol | 2 | 2006 | 38 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2013 | 26 | 0.030 |
Why?
| | Peripheral Arterial Disease | 1 | 2020 | 475 | 0.030 |
Why?
| | Models, Molecular | 2 | 2013 | 1570 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2426 | 0.030 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2012 | 56 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2012 | 45 | 0.020 |
Why?
| | Mothers | 1 | 2019 | 754 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1995 | 385 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 684 | 0.020 |
Why?
| | Laparoscopy | 1 | 2017 | 466 | 0.020 |
Why?
| | Leucovorin | 1 | 2012 | 81 | 0.020 |
Why?
| | Heart Rate | 2 | 2009 | 822 | 0.020 |
Why?
| | Complement C3 | 1 | 2013 | 209 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 98 | 0.020 |
Why?
| | Vascular System Injuries | 1 | 2013 | 71 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 73 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 7 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Asialoglycoprotein Receptor | 2 | 2006 | 7 | 0.020 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2013 | 150 | 0.020 |
Why?
| | Fear | 1 | 2015 | 338 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 199 | 0.020 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3715 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 26 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2012 | 195 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 31 | 0.020 |
Why?
| | Phenobarbital | 1 | 1991 | 19 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 789 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 1991 | 22 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1627 | 0.020 |
Why?
| | Hemodynamics | 1 | 2017 | 1113 | 0.020 |
Why?
| | Actins | 2 | 2007 | 416 | 0.020 |
Why?
| | Proteolysis | 1 | 2012 | 177 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 171 | 0.020 |
Why?
| | Darunavir | 1 | 2011 | 19 | 0.020 |
Why?
| | Heart Ventricles | 2 | 2007 | 788 | 0.020 |
Why?
| | Dealkylation | 1 | 1991 | 3 | 0.020 |
Why?
| | Femoral Artery | 1 | 2013 | 179 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2013 | 192 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 558 | 0.020 |
Why?
| | Glucuronates | 1 | 1991 | 5 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2013 | 271 | 0.020 |
Why?
| | Contrast Media | 1 | 1995 | 467 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 89 | 0.020 |
Why?
| | Spectrometry, Mass, Fast Atom Bombardment | 1 | 1991 | 8 | 0.020 |
Why?
| | Fluorouracil | 1 | 2012 | 208 | 0.020 |
Why?
| | Spectrophotometry, Infrared | 1 | 1991 | 54 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 1991 | 26 | 0.020 |
Why?
| | Centrifugation | 1 | 1991 | 30 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 191 | 0.020 |
Why?
| | Immunoenzyme Techniques | 3 | 1996 | 219 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2016 | 579 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2013 | 377 | 0.020 |
Why?
| | Food Analysis | 1 | 2011 | 26 | 0.020 |
Why?
| | Alfentanil | 1 | 2010 | 3 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2607 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2011 | 112 | 0.020 |
Why?
| | Aldehydes | 1 | 1991 | 145 | 0.020 |
Why?
| | Pain Perception | 1 | 2010 | 24 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 622 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2016 | 1079 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2828 | 0.020 |
Why?
| | Mice, Inbred DBA | 1 | 2010 | 200 | 0.020 |
Why?
| | Cell Division | 3 | 2001 | 794 | 0.020 |
Why?
| | Serologic Tests | 1 | 2010 | 54 | 0.020 |
Why?
| | Alleles | 1 | 2013 | 891 | 0.020 |
Why?
| | Blood | 2 | 2000 | 107 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 886 | 0.020 |
Why?
| | Protein Conformation | 1 | 2013 | 934 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 158 | 0.020 |
Why?
| | Spinacia oleracea | 1 | 2009 | 9 | 0.020 |
Why?
| | Granuloma | 1 | 2010 | 92 | 0.020 |
Why?
| | Proteins | 1 | 1995 | 1009 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2010 | 138 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 81 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2011 | 179 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 363 | 0.020 |
Why?
| | Prostaglandins A | 1 | 2009 | 10 | 0.020 |
Why?
| | Succinic Acid | 1 | 2009 | 37 | 0.020 |
Why?
| | Insulin Lispro | 1 | 2009 | 39 | 0.020 |
Why?
| | Serbia | 1 | 2008 | 7 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2009 | 91 | 0.020 |
Why?
| | Deoxyglucose | 1 | 2009 | 53 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 110 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 202 | 0.020 |
Why?
| | Bronchoscopy | 2 | 2000 | 223 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 366 | 0.020 |
Why?
| | Urinalysis | 1 | 2009 | 77 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 660 | 0.020 |
Why?
| | Cohort Studies | 1 | 2019 | 5742 | 0.020 |
Why?
| | Osmotic Pressure | 1 | 2008 | 38 | 0.020 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 41 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 335 | 0.020 |
Why?
| | Naloxone | 1 | 2009 | 122 | 0.020 |
Why?
| | Monocrotaline | 1 | 2007 | 28 | 0.020 |
Why?
| | HSP27 Heat-Shock Proteins | 1 | 2007 | 14 | 0.020 |
Why?
| | HIV-1 | 1 | 2013 | 864 | 0.020 |
Why?
| | Fasting | 1 | 2009 | 281 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 843 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 331 | 0.020 |
Why?
| | T-Lymphocytes | 2 | 2004 | 1996 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2007 | 48 | 0.020 |
Why?
| | Animals, Outbred Strains | 1 | 2006 | 5 | 0.020 |
Why?
| | Technetium | 1 | 2006 | 10 | 0.020 |
Why?
| | Radiography | 2 | 2000 | 822 | 0.020 |
Why?
| | Antibodies, Heterophile | 1 | 2006 | 14 | 0.020 |
Why?
| | Systole | 1 | 2007 | 189 | 0.020 |
Why?
| | Cell Size | 2 | 1997 | 91 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1988 | 307 | 0.020 |
Why?
| | Dosage Forms | 2 | 1996 | 11 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 294 | 0.020 |
Why?
| | Serum Albumin, Human | 1 | 2006 | 6 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2006 | 37 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 4 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 23 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2006 | 118 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 38 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1272 | 0.020 |
Why?
| | Insulin, Regular, Human | 1 | 2006 | 43 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 63 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.020 |
Why?
| | Muscle, Smooth | 1 | 2007 | 155 | 0.020 |
Why?
| | Portal System | 1 | 2006 | 14 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 812 | 0.020 |
Why?
| | Random Allocation | 1 | 2007 | 353 | 0.020 |
Why?
| | Insulin, Long-Acting | 1 | 2006 | 63 | 0.020 |
Why?
| | Cold Ischemia | 1 | 2006 | 30 | 0.020 |
Why?
| | Electroencephalography | 1 | 2009 | 423 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 976 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 90 | 0.020 |
Why?
| | Biopsy | 2 | 2000 | 1129 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2006 | 239 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2844 | 0.010 |
Why?
| | Myocardial Contraction | 1 | 2007 | 341 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2009 | 347 | 0.010 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2006 | 81 | 0.010 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 201 | 0.010 |
Why?
| | Drug Compounding | 1 | 2005 | 101 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2006 | 329 | 0.010 |
Why?
| | Escherichia coli | 1 | 2009 | 815 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1996 | 443 | 0.010 |
Why?
| | Travel | 1 | 2006 | 130 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 107 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 514 | 0.010 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2004 | 9 | 0.010 |
Why?
| | Treatment Failure | 1 | 2005 | 356 | 0.010 |
Why?
| | Motor Skills | 1 | 1985 | 97 | 0.010 |
Why?
| | Gene Expression | 1 | 2009 | 1502 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1062 | 0.010 |
Why?
| | Polymers | 1 | 2008 | 490 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2009 | 2167 | 0.010 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 553 | 0.010 |
Why?
| | Blood Coagulation | 1 | 2006 | 255 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 240 | 0.010 |
Why?
| | Absorption | 1 | 2003 | 63 | 0.010 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2003 | 32 | 0.010 |
Why?
| | Prevalence | 1 | 2010 | 2734 | 0.010 |
Why?
| | Stroke Volume | 1 | 2007 | 612 | 0.010 |
Why?
| | Adenosine Diphosphate | 1 | 2003 | 79 | 0.010 |
Why?
| | NFATC Transcription Factors | 1 | 2004 | 95 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 534 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 165 | 0.010 |
Why?
| | Coronary Circulation | 1 | 2003 | 143 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1070 | 0.010 |
Why?
| | Alanine | 1 | 2003 | 152 | 0.010 |
Why?
| | gamma-Glutamyltransferase | 2 | 1994 | 43 | 0.010 |
Why?
| | Chromatography, Gas | 1 | 2002 | 33 | 0.010 |
Why?
| | Hospitals, University | 1 | 2003 | 182 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 1995 | 3566 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2003 | 198 | 0.010 |
Why?
| | Alkaline Phosphatase | 2 | 1994 | 148 | 0.010 |
Why?
| | Rhodamine 123 | 1 | 2001 | 5 | 0.010 |
Why?
| | B7-2 Antigen | 1 | 2001 | 27 | 0.010 |
Why?
| | Microcirculation | 1 | 2002 | 149 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 2001 | 34 | 0.010 |
Why?
| | Transfection | 1 | 2003 | 945 | 0.010 |
Why?
| | Atrial Fibrillation | 1 | 2006 | 388 | 0.010 |
Why?
| | Calorimetry | 1 | 2001 | 70 | 0.010 |
Why?
| | Chronic Disease | 1 | 2007 | 1793 | 0.010 |
Why?
| | Molecular Conformation | 1 | 2001 | 145 | 0.010 |
Why?
| | Quantum Theory | 1 | 2001 | 78 | 0.010 |
Why?
| | Cell Membrane | 2 | 1995 | 738 | 0.010 |
Why?
| | Coronary Vessels | 1 | 2002 | 248 | 0.010 |
Why?
| | Coloring Agents | 1 | 2000 | 87 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2000 | 66 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1786 | 0.010 |
Why?
| | Autopsy | 1 | 2000 | 95 | 0.010 |
Why?
| | Doxorubicin | 1 | 2001 | 362 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 2 | 1991 | 50 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 984 | 0.010 |
Why?
| | Islets of Langerhans | 1 | 2006 | 803 | 0.010 |
Why?
| | Diuretics, Osmotic | 1 | 1999 | 2 | 0.010 |
Why?
| | Crotonates | 1 | 1999 | 5 | 0.010 |
Why?
| | Toluidines | 1 | 1999 | 7 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2833 | 0.010 |
Why?
| | Remission Induction | 1 | 2000 | 288 | 0.010 |
Why?
| | Vinblastine | 1 | 1999 | 71 | 0.010 |
Why?
| | Capsules | 2 | 1990 | 38 | 0.010 |
Why?
| | Ultrasonography | 1 | 2003 | 759 | 0.010 |
Why?
| | Thermodynamics | 1 | 2001 | 407 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 342 | 0.010 |
Why?
| | Indicators and Reagents | 1 | 1999 | 106 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2004 | 712 | 0.010 |
Why?
| | Isoxazoles | 1 | 1999 | 54 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 1999 | 431 | 0.010 |
Why?
| | Aniline Compounds | 1 | 1999 | 102 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 1999 | 530 | 0.010 |
Why?
| | Radiography, Thoracic | 1 | 1999 | 167 | 0.010 |
Why?
| | Binding Sites | 1 | 2001 | 1303 | 0.010 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2000 | 446 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 665 | 0.010 |
Why?
| | Cytosol | 1 | 1997 | 226 | 0.010 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 1996 | 2 | 0.010 |
Why?
| | Acetic Anhydrides | 1 | 1996 | 3 | 0.010 |
Why?
| | Azathioprine | 1 | 1996 | 54 | 0.010 |
Why?
| | Computer Simulation | 1 | 2001 | 978 | 0.010 |
Why?
| | Tissue Donors | 1 | 2000 | 425 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1502 | 0.010 |
Why?
| | Administration, Topical | 1 | 1996 | 151 | 0.010 |
Why?
| | Membrane Lipids | 1 | 1996 | 91 | 0.010 |
Why?
| | Ophthalmic Solutions | 1 | 1996 | 75 | 0.010 |
Why?
| | Acetonitriles | 1 | 1995 | 11 | 0.010 |
Why?
| | Bile Canaliculi | 1 | 1995 | 12 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1719 | 0.010 |
Why?
| | Albumins | 1 | 1996 | 114 | 0.010 |
Why?
| | Antifungal Agents | 1 | 1996 | 136 | 0.010 |
Why?
| | Cornea | 1 | 1996 | 138 | 0.010 |
Why?
| | Immunoblotting | 1 | 1995 | 308 | 0.010 |
Why?
| | Fetuins | 1 | 1995 | 2 | 0.010 |
Why?
| | Cataract Extraction | 1 | 1996 | 98 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 1995 | 41 | 0.010 |
Why?
| | Ferrosoferric Oxide | 1 | 1995 | 27 | 0.010 |
Why?
| | Cytomegalovirus Infections | 1 | 1996 | 192 | 0.010 |
Why?
| | Skin | 1 | 1999 | 752 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1994 | 180 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1994 | 189 | 0.010 |
Why?
| | Vasodilator Agents | 1 | 1996 | 331 | 0.010 |
Why?
| | Cell Adhesion | 1 | 1995 | 466 | 0.010 |
Why?
| | Vinca Alkaloids | 1 | 1993 | 6 | 0.010 |
Why?
| | Affinity Labels | 1 | 1993 | 26 | 0.010 |
Why?
| | Succinimides | 1 | 1993 | 19 | 0.010 |
Why?
| | Daunorubicin | 1 | 1993 | 26 | 0.010 |
Why?
| | Collagen | 1 | 1996 | 452 | 0.010 |
Why?
| | Algorithms | 1 | 2001 | 1704 | 0.010 |
Why?
| | Cricetulus | 1 | 1993 | 109 | 0.010 |
Why?
| | CHO Cells | 1 | 1993 | 161 | 0.010 |
Why?
| | Bile Acids and Salts | 1 | 1994 | 200 | 0.010 |
Why?
| | Cricetinae | 1 | 1993 | 289 | 0.010 |
Why?
| | Norpregnenes | 1 | 1992 | 4 | 0.010 |
Why?
| | Drug Resistance | 1 | 1993 | 169 | 0.010 |
Why?
| | Tritium | 1 | 1992 | 76 | 0.010 |
Why?
| | Water | 1 | 1995 | 460 | 0.010 |
Why?
| | Glutamate Dehydrogenase | 1 | 1991 | 4 | 0.010 |
Why?
| | Cholinesterases | 1 | 1991 | 10 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1991 | 171 | 0.010 |
Why?
| | Aspartate Aminotransferases | 1 | 1991 | 90 | 0.010 |
Why?
| | Alanine Transaminase | 1 | 1991 | 157 | 0.010 |
Why?
| | Oils | 1 | 1990 | 21 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1993 | 771 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1994 | 786 | 0.000 |
Why?
| | Antigen-Antibody Reactions | 1 | 1987 | 55 | 0.000 |
Why?
| | Gelatin | 1 | 1988 | 52 | 0.000 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 98 | 0.000 |
Why?
| | CD3 Complex | 1 | 1987 | 106 | 0.000 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 1987 | 718 | 0.000 |
Why?
|
|
Christians's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|